Wuhan Yingnuo Pharmaceutical Technology

Wuhan Yingnuo Pharmaceutical Technology is a clinical-stage biotechnology company based in Wuhan, China, dedicated to the discovery and development of innovative small molecule drugs. Founded in 2015, the company focuses on addressing significant unmet medical needs in oncology, metabolic diseases, and inflammatory disorders. Wuhan Yingnuo utilizes a proprietary drug discovery platform that integrates advanced medicinal chemistry with efficient preclinical evaluation processes. Its lead candidate, YN-001, is a highly selective small molecule inhibitor currently being evaluated for the treatment of various solid tumors. The company is strategically located in the Wuhan East Lake High-tech Development Zone, also known as Optics Valley, benefiting from a robust regional life sciences ecosystem. Through internal R&D and strategic partnerships, Wuhan Yingnuo aims to deliver high-quality therapeutic solutions to patients globally.